Меню
Идёт набор NCT05129748

Efficacy of Sodium Thiosulfate and Mannitol in Reducing Ototoxicity in Adult Patients Receiving Cisplatin Chemotherapy

Фаза II С лечением Ototoxic Hearing Loss

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Sodium Thiosulfate + Mannitol.
Кому может быть актуально
Состояния в реестре: Ototoxic Hearing Loss. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Канада
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

A Multicenter Randomized Phase II Clinical Trial of the Efficacy of Sodium Thiosulfate and Mannitol in Reducing Ototoxicity in Adult Patients Receiving Cisplatin Chemotherapy

Обзор

One common side effect of cisplatin chemotherapy is ototoxicity. The drugs sodium thiosulfate and mannitol may protect against cisplatin-induced hearing loss. Specifically, sodium thiosulfate has been found to protect the cells in the inner ear, and may therefore prevent hearing loss. Mannitol can help sodium thiosulfate enter the inner ear, and ponteially increase the effectiveness of sodium thiosulfate. This study aims to assess the efficacy of sodium thiosulfate and mannitol to reduce the hearing impairment caused by cisplatin chemotherapy.

Подробное описание

Randomized phase II clinical trial: with 1:1 randomization between cisplatin alone, and cisplatin + sodium thiosulfate and mannitol. Participants will first be recruited into a 2-year pilot feasibility study of 24 patients (12 in each arm). The pilot study will be performed to evaluate the feasibility of the trial as defined by the following factors: treatment outcomes, occurrence of adverse events, logistics of treatment delivery, as well as dropout and recruitment rates. The results from the pilot study will support the safety, efficacy, and effectiveness of the sodium thiosuldate and mannitol treatment, confirm feasibility using the factors mentioned above, and serve as an earlier-phase developmental function to enhance the probability of success of the subsequent clinical trial. Participants will complete various pre-treatment hearing tests. Participants will receive sodium thiosulfate and mannitol 4 - 8 hours following chemotherapy treatment. The control group will not receive the experimental intervention. Follow-up hearing tests will be performed at select time intervals following completion of their cancer treatment.

Вмешательства

  • Препарат Sodium Thiosulfate + Mannitol
    Drug delivery will be sequential, where Mannitol will be infused over 30 minutes and Sodium Thiosulfate will be infused over 15 minutes.

Первичные конечные точки

  • Improvement in hearing threshold with sodium thiosulfate and mannitol administration [Срок оценки: 2 months]
Вторичные конечные точки (4)
  • To monitor potential oncological impact of sodium thiosulfate and mannitol on long-term renal clearance [Срок оценки: 12 months]
  • To monitor potential oncological impact of sodium thiosulfate and mannitol on disease free survival [Срок оценки: 12 months]
  • To monitor potential oncological impact of sodium thiosulfate and mannitol on overall survival [Срок оценки: 12 months]
  • To assess the short and long-term adverse event reporting from combination of sodium thiosulfate, mannitol and cisplatin. [Срок оценки: 12 months]

Критерии участия

Критерии включения

  • Patients undertaking systemic cisplatin therapy as part of their cancer treatment
  • Age ≥ 18
  • Willing to provide informed consent
  • ECOG performance status 0-2
  • For female of child-bearing potential, a negative pregnancy test (beta-HCG) prior to study treatment is required
  • Any patient who is of reproductive age should provide written agreement to use adequate contraception for the duration of the trial

Критерии исключения

  • Age less than 18
  • Preexisting severe to profound sensorineural hearing loss (unilateral or bilateral) (speech reception threshold >70dB, or word recognition score <50%) as confirmed with an audiogram
  • History of Meniere's or fluctuating hearing loss
  • Asymmetrical hearing loss (bone conduction threshold difference of: (a) 20 dB threshold difference at a single frequency, (b) 15 dB threshold difference at 2 frequencies, (c) 10 dB threshold difference at 3 frequencies
  • Abnormal renal function (creatinine clearance <60 ml/min)
  • Abnormal liver function (liver function tests (ALT and ALP) >2.5 times upper limit of normal without liver metastasis and >5 times upper limit of normal with liver metastasis
  • Previous hypersensitivity to STS or mannitol
  • Pregnant and/or nursing women
  • Patient unable to follow the protocol for any reason

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Простое слепое
Основная цель
Профилактика

Центры проведения

Канада · 1 центр
  • Sunnybrook Health Sciences Centre — Toronto

Идентификаторы

NCT: NCT05129748 · 1818

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗